Fibrin aggregation

Fibrin aggregation refers to the process where fibrin monomers, generated from fibrinogen by the enzymatic action of thrombin, spontaneously polymerize to form protofibrils that then aggregate laterally, resulting in the formation of a fibrous network. This stable fibrin mesh is essential for the structural integrity of blood clots, providing the scaffolding that entraps platelets and blood cells to stop bleeding (hemostasis). Fibrin clots are dynamic structures whose properties can be modulated by mechanical forces, environmental factors, and interactions with cellular components (such as platelets). Dysregulation of fibrin aggregation is central to the pathogenesis of both thrombosis and certain bleeding disorders. Fibrin aggregation is a process, not a canonical molecular target, and should generally be mapped to the structural protein fibrin or the broader fibrin network. If the intention is to reference a drug target, that target would typically be fibrin (as substrate for fibrinolytic drugs), not the aggregation process itself. The research and clinical context does not recognize "Fibrin aggregation" as a canonical molecular target. It is instead a descriptive term for a molecular process. Structured drug discovery databases and target annotation resources classify fibrin (not fibrin aggregation) as the drug substrate/target in thrombolytic and antifibrinolytic therapy.

Other names

Fibrin clotFibrin networkFactor IaFibrin polymerFibrin mesh

Fibrinolytic agents (e.g., tPA) bind to fibrin and convert plasminogen to plasmin, initiating clot lysis; antifibrinolytics (e.g., tranexamic acid) block lysine binding sites on fibrin, inhibiting fibrinolysis